TORONTO, May 5 /PRNewswire-FirstCall/ -- GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced its shareholders recently elected two additional members to its Board of Directors, Mr. Harry A. Glorikian and Ms. Fran Tuttle. They join Mr. Rory Riggs, Mr. James Howard-Tripp, Mr. Garth MacRae, Dr. Heiner Dreismann, Dr. C. C. Liew and Dr. K. Wayne Marshall on the Company's Board of Directors.
"We are pleased to welcome Mr. Glorikian and Ms. Tuttle to the GeneNews Board of Directors. Mr. Glorikian is currently the managing partner of Scientia Advisors, an international management and strategy consulting firm with a concentration in biotechnology and life sciences and Ms. Tuttle is President and Chief Executive Officer of HX Diagnostics, a diagnostics company in Emeryville, Ca., specialising in rapid diagnostics for seasonal and emerging infectious diseases," said K. Wayne Marshall, MD, PhD, President and Chief Executive Officer of GeneNews. "Their extensive experience in molecular diagnostics makes them timely additions to our Board as we prepare for the commercialization of our laboratory developed test (LDT) version of ColonSentry(TM), a blood-based molecular test to assess current risk for colorectal cancer. We expect to launch ColonSentry in Canada in the third quarter of this year."
Prior to becoming the Managing Partner at Scientia Advisors, Mr. Glorikian spent more than 8 years at Applied Biosystems in various roles, completing his tenure as Senior Manager, New Technology Assessment/Business Development. He was also the National Sales Manager for Signet Laboratories and a founder of X-Cell Laboratories, a clinical reference laboratory in San Francisco.
Ms. Tuttle is currently the President and CEO of HX Diagnostics. Throughout her career, she has developed and launched several major diagnostics products and had corporate experience at leading diagnostic companies including Bayer, Corning, Inc., Novartis, and Chiron. Ms. Tuttle was a Senior Vice President at Bayer Diagnostics responsible for a worldwide business of $400M. Most recently Ms. Tuttle was President and CEO of Protedyne, Inc., a robotics company developing automation solutions for molecular diagnostics and drug discovery, which was sold to LabCorp in 2007.
About GeneNews --------------
GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews' first product in development, ColonSentry(TM), is a convenient and patient-friendly blood-based test that can assess an individual's current risk for colorectal cancer. For more information on GeneNews, visit http://www.genenews.com/.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.
